RxDoctor Payments Data

Amanda Pleimann-King, DO

Family Medicine · Cape Girardeau, MONPI 1659722155

Payments from drug & device makers

$1,879in general payments, 2019–2025

Across 83 payments — averaging $22.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$417
  • Lilly USA, LLC$272
  • Bayer$154
  • Gilead$150
  • Novartis$132
  • Novo Nordisk$126
  • plus $627 from 17 others

What the payments were for

  • Food & beverage$1,86099%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,879 in reported general payments places this provider in the 70th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$6,684
Medicare patients
95
Services billed
319

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide69$76,496
JardianceEmpagliflozin57$49,296
FarxigaDapagliflozin Propanediol47$38,217
JanuviaSitagliptin Phosphate22$11,934
MounjaroTirzepatide11$10,927
TradjentaLinagliptin15$10,608
Tresiba Flextouch U-100Insulin Degludec16$7,302
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$4,046
Cimetidine23$2,001
Gabapentin124$1,734
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,681
Albuterol Sulfate HfaAlbuterol Sulfate57$1,160
Omeprazole65$970
Atorvastatin Calcium145$811
Pantoprazole Sodium122$811

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$126$76,49669 claims
Boehringer IngelheimJardiance, Tradjenta$64$59,90472 claims
AstraZenecaFarxiga$62$38,21747 claims
Lilly USA, LLCMounjaro$272$10,92711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Cape Girardeau

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →